Table 31.5: Cost-Effectiveness Results: Depression
Cost-Effectiveness Results: Depression| Model definition: | | | Treatment setting: primary health care | World Bank region | | Treatment coverage: 50 percent | Sub-Saharan Africa | Latin America and the Caribbean | Middle East and North Africa | Europe and Central Asia | South Asia | East Asia and the Pacific | | Total effect (DALYs averted per year per 1 million population) | | Current situation | 133 | 264 | 218 | 308 | 218 | 243 | | Episodic treatment: older antidepressant drug (TCA) | 599 | 995 | 920 | 874 | 987 | 891 | | Episodic treatment: newer antidepressant drug (SSRI) | 632 | 1,049 | 971 | 925 | 1,042 | 941 | | Episodic psychosocial treatment | 624 | 1,036 | 958 | 936 | 1,028 | 927 | | Episodic psychosocial treatment plus older antidepressant | 745 | 1,237 | 1,144 | 1,100 | 1,228 | 1,107 | | Episodic psychosocial treatment plus newer antidepressant | 745 | 1,237 | 1,144 | 1,100 | 1,228 | 1,107 | | Maintenance psychosocial treatment plus older antidepressant | 1,174 | 1,953 | 1,806 | 1,789 | 1,937 | 1,747 | | Maintenance psychosocial treatment plus newer antidepressant | 1,174 | 1,953 | 1,806 | 1,789 | 1,937 | 1,747 | | Total cost (US$ million per year per 1 million population) | | Current situation | 0.36 | 0.90 | 0.63 | 0.74 | 0.56 | 0.67 | | Episodic treatment: older antidepressant drug (TCA) | 0.30 | 1.28 | 0.96 | 0.81 | 0.47 | 0.47 | | Episodic treatment: newer antidepressant drug (SSRI) | 0.66 | 1.86 | 1.47 | 1.39 | 1.04 | 0.99 | | Episodic psychosocial treatment | 0.37 | 1.67 | 1.27 | 0.97 | 0.55 | 0.53 | | Episodic psychosocial treatment plus older antidepressant | 0.50 | 1.96 | 1.53 | 1.21 | 0.77 | 0.72 | | Episodic psychosocial treatment plus newer antidepressant | 0.90 | 2.60 | 2.10 | 1.85 | 1.40 | 1.29 | | Maintenance psychosocial treatment plus older antidepressant | 0.96 | 3.44 | 2.77 | 2.19 | 1.45 | 1.38 | | Maintenance psychosocial treatment plus newer antidepressant | 1.80 | 4.80 | 3.99 | 3.56 | 2.81 | 2.59 | | Cost-effectiveness (US$ per DALY averted) | | Current situation | 2,692 | 3,414 | 2,905 | 2,391 | 2,546 | 2,777 | | Episodic treatment: older antidepressant drug (TCA) | 505 | 1,288 | 1,039 | 929 | 478 | 533 | | Episodic treatment: newer antidepressant drug (SSRI) | 1,042 | 1,771 | 1,516 | 1,501 | 1,003 | 1,048 | | Episodic psychosocial treatment | 592 | 1,611 | 1,330 | 1,035 | 537 | 570 | | Episodic psychosocial treatment plus older antidepressant | 674 | 1,586 | 1,335 | 1,104 | 627 | 653 | | Episodic psychosocial treatment plus newer antidepressant | 1,203 | 2,101 | 1,834 | 1,682 | 1,140 | 1,161 | | Maintenance psychosocial treatment plus older antidepressant | 817 | 1,760 | 1,533 | 1,226 | 749 | 788 | | Maintenance psychosocial treatment plus newer antidepressant | 1,535 | 2,459 | 2,211 | 1,990 | 1,449 | 1,481 |
Source: Authors' own estimates.
Note: Intervention data in bold are the most cost-effective treatments of choice. |
|
